ABI 01
Alternative Names: ABI-01Latest Information Update: 28 Jun 2024
At a glance
- Originator Avanti Biosciences
- Class Antidementias; Catechins; Small molecules
- Mechanism of Action DYRK kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 28 Jun 2024 No recent reports of development identified for research development in Alzheimer's-disease in USA
- 23 Nov 2022 Avanti Biosciences receives SBIR Fast-Track award from the National Institute of Aging (NIA) for ABI 01 development in Alzheimer's disease
- 05 May 2019 Avanti Biosciences receives second phase of the fast track SBIR grants from the National Institute of Aging (NIA) for work on Alzheimer's disease (Avanti Biosciences website, November 2022)